Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-002074-23
    Sponsor's Protocol Code Number:CAFQ056A2223
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-02-06
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2011-002074-23
    A.3Full title of the trial
    13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson?s disease
    Estudio doble ciego, controlado con placebo, de dosis fija, multicéntrico, de 13 semanas de seguimiento para evaluar la eficacia y seguridad de la liberación modificada de AFQ056 en la reducción de las discinesias inducidas por levodopa, moderadas a graves, en pacientes con enfermedad de Parkinson
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
    Evaluación de la eficacia y seguridad de la liberación modificada de AFQ056 en pacientes con Parkinson y discinesias inducidas por levodopa.
    A.4.1Sponsor's protocol code numberCAFQ056A2223
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT01491932
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovartis Farmacéutica, S.A.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNovartis Pharma Services AG
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNovartis Farmacéutica, S.A.
    B.5.2Functional name of contact pointJordi Guillén
    B.5.3 Address:
    B.5.3.1Street AddressGran Via de les Corts Catalanes, 764
    B.5.3.2Town/ cityBarcelona
    B.5.3.3Post code08013
    B.5.3.4CountrySpain
    B.5.4Telephone number+34933064953
    B.5.5Fax number+34933064274
    B.5.6E-mailjordi.guillen@novartis.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAFQ056
    D.3.2Product code AFQ056
    D.3.4Pharmaceutical form Modified-release tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 543906-09-8
    D.3.9.2Current sponsor codeAFQ056
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAFQ056
    D.3.2Product code AFQ056
    D.3.4Pharmaceutical form Modified-release tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 543906-09-8
    D.3.9.2Current sponsor codeAFQ056
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAFQ056
    D.3.2Product code AFQ056
    D.3.4Pharmaceutical form Modified-release tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 543906-09-8
    D.3.9.2Current sponsor codeAFQ056
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAFQ056
    D.3.2Product code AFQ056
    D.3.4Pharmaceutical form Modified-release tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 543906-09-8
    D.3.9.2Current sponsor codeAFQ056
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAFQ056
    D.3.2Product code AFQ056
    D.3.4Pharmaceutical form Modified-release tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 543906-09-8
    D.3.9.2Current sponsor codeAFQ056
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboModified-release capsule, hard
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboModified-release capsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    L-dopa induced dyskinesias in patients with Parkinson's disease
    Discinesias inducidas por levodopa en pacientes con enfermedad de Parkinson
    E.1.1.1Medical condition in easily understood language
    Parkinson's Patients with L-dopa induced dyskinesias
    Discinesias inducidas por levodopa en pacientes con enfermedad de Parkinson
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level HLT
    E.1.2Classification code 10013929
    E.1.2Term Dyskinesias and movement disorders NEC
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess how titration of modified release AFQ056 at 2-week intervals to a target dose of 200 mg b.i.d. or 150 mg b.i.d. versus placebo affects the tolerability profile in patients with moderate to severe PD-LID.

    To demonstrate the anti-dyskinetic efficacy, as measured by change from baseline to Week 12 in the modified AIMS (Abnormal Involuntary Movement Scale) total score, of titration of modified release AFQ056 at 2-week intervals to a target dose of 200 mg b.i.d. or 150 mg b.i.d. versus placebo in patients with moderate to severe PD-LID.
    Evaluar de qué manera el ajuste de la liberación modificada de AFQ056 a intervalos de 2 semanas hasta una dosis objetivo de 200 mg b.i.d. ó 150 mg b.i.d. versus placebo afecta al perfil de tolerabilidad en pacientes con DIL-EP moderadas a graves.
    Demostrar la eficacia en la reducción de las discinesias, medida por el cambio en la puntuación total de la AIMS modificada (Escala de Movimientos Involuntarios Anormales) desde la visita basal hasta la Semana 12, del ajuste de la liberación modificada de AFQ056 a intervalos de 2 semanas hasta una dosis objetivo de 200 mg b.i.d. ó 150 mg b.i.d. versus placebo en pacientes con DIL-EP moderadas a graves.
    E.2.2Secondary objectives of the trial
    To assess the anti-dyskinetic efficacy as measured by the UDysRS (Unified Dyskinesia Rating Scale), parts I-IV

    To assess the anti-dyskinetic efficacy as measured by the Revised Lang-Fahn Activities of Daily Living Dyskinesia Scale (LFADLDS) patient and caregiver versions

    To evaluate change from baseline on patient?s disability caused by the dyskinesia as assessed by a clinician-rated global impression of change (CGIC)

    To evaluate the Total ON- and OFF-times and ON-time with dyskinesia and with troublesome dyskinesias (patient diary)

    To evaluate anti-dyskinetic efficacy as measured by items 32, 33 and 34 of Part IV of the UPDRS (Unified Parkinson?s Disease Rating Scale)

    To evaluate the safety of AFQ056 as measured by changes in vital signs, laboratory values and ECGs and percentages of treatment-emergent adverse events and serious adverse events

    To evaluate the effect of AFQ056 on the underlying symptoms of Parkinson?s disease
    ?Evaluar la eficacia antidiscinética medida mediante la UDysRS partes I-IV
    ?Evaluar la eficacia en la reducción de las discinesias medida con la LFADLDS, versiones del paciente y cuidador
    ?Evaluar el cambio desde la visita basal en la discapacidad del paciente causada por las discinesias, valorada mediante la CGIC
    ?Evaluar los tiempos ?on? y ?off? totales, tiempo ?on? con discinesias y tiempo ?on? con discinesias molestas (diario del paciente)
    ?Evaluar la eficacia en la reducción de las discinesias medida por los ítems 32, 33 y 34 de la Parte IV de la UPDRS
    ?Evaluar la seguridad de AFQ056 valorada mediante los cambios en las constantes vitales, en los valores de laboratorio y ECGs y en los porcentajes de acontecimientos adversos y acontecimientos adversos graves surgidos a causa del tratamiento
    ?Evaluar el efecto de AFQ056 en los síntomas subyacentes de la enfermedad de Parkinson
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Males and Females 30-80 years old
    - Use of highly effective methods of contraception during study in women of childbearing potential
    - Outpatients
    - Clinical diagnosis of Parkinson?s Disease according to UK Parkinson?s Disease Society Brain Bank Clinical Diagnosis criteria
    - Score of >/= 2 on UPDRS items 32 and 33
    -Dyskinesias for at least 3 months before baseline
    -On stable treatment regimen with L-dopa and other anti-parkinsonian treatment for 4 weeks prior to baseline
    - Demonstrate capacity to complete accurate diary ratings
    - Patients who have a primary caregiver willing to assess the condition of the patient throughout the study in accordance with protocol requirements
    1.Deberá obtenerse el consentimiento informado por escrito antes de que se realice ninguno de los procedimientos relacionados con el estudio en la Selección.
    2.Hombres y mujeres, de 30-80 años de edad (ambas inclusive)
    3.Las mujeres en edad fértil, definidas como todas las mujeres fisiológicamente capaces de quedarse embarazadas, deberán utilizar métodos anticonceptivos altamente eficaces durante la administración y durante las 96 horas siguientes a la retirada de la medicación del estudio. Los métodos anticonceptivos altamente eficaces incluyen:
    ?Abstinencia total (cuando ésta coincide con el estilo de vida preferido y habitual de la paciente). [La abstinencia periódica (p. ej., calendario, ovulación, métodos sintotérmicos, postovulación) y la marcha atrás no se consideran métodos anticonceptivos aceptables]
    ?Esterilización de la mujer (ha sido sometida a ooforectomía bilateral quirúrgica, con o sin histerectomía) o ligadura de trompas al menos seis semanas antes de tomar el tratamiento del estudio. Si sólo se ha realizado ooforectomía, sólo cuando se ha confirmado el estado reproductivo de la mujer mediante el seguimiento de la evaluación del nivel hormonal.
    ?Esterilización del varón (al menos 6 meses antes de la selección) [Para las pacientes mujeres participantes en el estudio, la pareja varón vasectomizado debería ser la única pareja de dicha paciente].
    ?Uso de una combinación de cualquiera de los dos de los siguientes métodos (a+b):
    a.Colocación de un dispositivo intrauterino (DIU) o un sistema intrauterino (SIU)
    b.b) Métodos anticonceptivos de barrera: Preservativo o capuchón oclusivo (diafragma o capuchón cervical) con espuma/gel/película/crema espermicida/supositorio vaginal
    Debido a la falta de datos relativos a las posibles interacciones medicamentosas entre AFQ056 y los anticonceptivos orales, los anticonceptivos hormonales que se inyectan o implantan o administran por vía oral o transdérmica no se consideran métodos anticonceptivos eficaces.
    En este estudio se permitirá reclutar a mujeres que no estén en edad fértil sin que utilicen métodos anticonceptivos. Se considera que una mujer es posmenopáusica y no fértil si lleva 12 meses de amenorrea natural (espontánea) con un perfil clínico apropiado (p. ej., edad apropiada, antecedentes de síntomas vasomotores) o si ha sido sometida a ooforectomía bilateral quirúrgica (con o sin histerectomía) o ligadura de trompas al menos seis semanas antes. Si sólo se ha realizado ooforectomía, se considerará que la mujer no es fértil únicamente tras confirmarse el estado reproductivo de la mujer mediante el seguimiento de la evaluación del nivel hormonal.
    4.Pacientes ambulatorios, que residan en la comunidad (no se permite a los pacientes ingresados en centros asistenciales)
    5.Presentar un diagnóstico clínico de enfermedad de Parkinson según los criterios diagnósticos clínicos en la enfermedad de Parkinson de la UK Parkinson?s Disease Society Brain Bank (Apéndice 2)
    6.Puntuación ? 2 en el ítem 32 de la UPDRS (es decir, discinesias presentes durante más del 25% del tiempo) y puntuación ? 2 en el ítem 33 de la UPDRS (es decir, moderada o gravemente discapacitado)
    7.Inicio de las discinesias al menos 3 meses antes de la BL1
    8.Haber estado tomando levodopa durante al menos los 3 años anteriores a la BL1 o, si la duración del tratamiento es ? 3 años, en tal caso deberán haber mostrado una claro grado de respuesta (UPDRS, parte III) al tratamiento con levodopa
    9.Estar en régimen de tratamiento estable con levodopa y otro tratamiento antiparkinsoniano durante al menos las 4 semanas previas a la primera visita basal (BL1) con optimización de la dosis según lo determine el clínico que realice el reclutamiento. Además de este tratamiento estable, se permiten hasta tres dosis por semana de levodopa soluble o apomorfina subcutánea para optimizar el régimen de tratamiento para aliviar las fluctuaciones (períodos ?off?).
    10.Demostrar capacidad para rellenar, en una sesión formativa realizada en la consulta y durante el período basal previo a la aleatorización (BL2), el diario con puntuaciones exactas del tiempo ?on?/?off? y de las discinesias, obteniéndose al menos un 66% de concordancia entre el paciente y el investigador/coordinador el día en el que el paciente presentó un tiempo ?on? sin discinesias, ?on? con discinesias, y tiempo ?off?
    11.Tener un cuidador principal que esté dispuesto a aceptar la responsabilidad de evaluar la afección del paciente durante el estudio y a facilitar información para las evaluaciones de acuerdo con todos los requisitos del protocolo.
    E.4Principal exclusion criteria
    Atypical/secondary form of Parkinson?s disease
    - History of surgical treatment of PD, including deep brain stimulation
    - A score of 5 in the ?ON?- state on the Modified Hoehn and Yahr scale
    - Advanced, severe, or unstable disease other than PD
    - Evidence of dementia
    - Treatment with certain prohibited medications

    Other protocol-defined inclusion/exclusion criteria may apply.
    1.Signos clínicos que sugieran una forma atípica o secundaria de enfermedad de Parkinson (p. ej., parálisis supranuclear progresiva, atrofia multisistémica)
    2.Antecedentes de tratamiento quirúrgico debido a EP, incluida la estimulación cerebral
    3.Una puntuación de 5 en la evaluación del estado ?on? de la Escala modificada de Hoehn y Yahr Staging (UPDRS Parte V) en el período de selección
    4.Incapaz (en opinión del Investigador Principal) de mantener la dosis estable actual de sus medicaciones antiparkinsonianas durante el ensayo
    5.Cualquier enfermedad avanzada, grave o inestable (distinta a EP) que pueda interferir con las evaluaciones de los resultados del estudio principales y secundarios
    6.Antecedentes de enfermedad maligna de cualquier sistema orgánico (distinta a carcinoma basocelular de la piel localizado o cáncer de próstata no invasivo y no metastásico que haya sido tratado eficazmente), tratada o no tratada, en los últimos 5 años, independientemente de si existen indicios de recurrencia local o metástasis
    7.Signos de demencia (o MMSE ? 26 en la Selección)
    8.Trastorno depresivo mayor no tratado o ineficazmente tratado, o que actualmente presente alucinaciones/psicosis que precisen de tratamiento antipsicótico, y/o estados de confusión (DSM-IVR, Manual diagnóstico y estadístico de los trastornos mentales, 4ª edición, revisado)
    9.Tratamiento con cualquiera de los siguientes:
    ?Tratamiento previo con AFQ056
    ?Tratamiento con medicaciones concomitantes que sean inhibidores fuertes o moderados de CYP3A4 1 semana antes de la visita BL1 Apéndice 3)
    ?Tratamiento con medicaciones concomitantes que sean inductores fuertes o moderados de CYP3A4 1 semana antes de la visita BL1 Apéndice 3)
    ?Warfarina o digoxina 1 semana antes de la visita BL1
    ?Medicación anticolinérgica de acción central 1 semana antes de la visita BL1
    ?Amantadina en las 3 semanas previas a la visita BL1
    ?Metoclopramida en las 4 semanas previas a la visita BL1
    ?Tratamiento inestable con domperidona, antidepresivos, o ansiolíticos en las 6 semanas anteriores a la visita BL1. En este estudio pueden participar pacientes en tratamiento estable (? 6 semanas), según lo determinen los clínicos encargados del reclutamiento, con domperidona (que no exceda 30 mg/día), antidepresivos, y ansiolíticos.
    ?Neurolépticos típicos o atípicos en los 3 meses anteriores a la visita BL1
    ?Bombas de duodopa o apomorfina
    10.Uso de otros fármacos en investigación en 5 vidas media o en los 30 días de la visita BL1, lo que sea más largo
    11.Valores de laboratorio que incluyan AST, ALT, bilirrubina total o creatinina ? 1,5 X LSN (límite superior de normalidad) para el laboratorio central en la Selección y/o BL1
    12.Síndrome de QT largo o QTc > 450 mseg en hombres y > 470 mseg en mujeres en la Selección y/o BL1
    13.Antecedentes de hipersensibilidad a cualquiera de las medicaciones del estudio o a fármacos de clases químicas similares
    14.Mujeres embarazadas o en período de lactancia, donde el embarazo se define como el estado de una mujer después de la concepción y hasta la finalización de la gestación, confirmado con un resultado positivo en la prueba de laboratorio hCG
    E.5 End points
    E.5.1Primary end point(s)
    - Change in modified AIMS (Abnormal Involuntary Movement Scale) total score from baseline to Week 12

    - incidence rate of adverse events
    - time to onset of adverse events
    - The percentage of patients reaching and maintaining the target dose during the fixed dose treatment period
    -The percentage of patients discontinued during the up titration period due to AE
    - Cambio en la puntuación de la escala mAIMS de baseline a la semana 12
    - Incidencia de eventos adversos
    - tiempo hasta el inicio de los eventos adversos
    - porcentaje de pacientes que alcanzan y mantienen la dosis objetivo durante el periodo de tratamiento de dosis fija.
    - porcentaje de pacientes discontinuados durante el periodo de ajuste ascendente de la dosis debido a AAs
    E.5.1.1Timepoint(s) of evaluation of this end point
    -Change of AIMS (timeframe 12 weeks): (week -6 to -3; -2; 0; 6; 12; 13)


    - Monitored for the duration of the study which is 13 weeks
    - Monitored for the duration of the study which is 13 weeks
    - Assessed during the fixed dose treatment period of 6 weeks
    - Assessed during the up titration period of 6 weeks
    -Cambio en el AIMS (periodo de 12 semanas): (semanas -6 a -3; -2; 0; 6; 12; 13)
    - Minitorizado durante todo el ensayo (13 semanas)
    - Minitorizado durante todo el ensayo (13 semanas)
    - Valorado durante el periodo de tratamiento de dosis fija (6 semanas)
    - Valorado durante el periodo de ajuste ascendente de la dosis (6 semanas)
    E.5.2Secondary end point(s)
    The change in total score and sub-score of UDysRS Parts I, II, III, and IV from baseline to Week 12

    Change in Lang-Fahn Activities of Daily Living Dyskinesia Scale (LFADLDS) total score from baseline to Week 12

    Change in clinician-rated global impression of change (CGIC) score from baseline to Week 12

    Change from baseline Total ON- and OFF-times and ON-time with dyskinesia and with troublesome dyskinesias (patient diary) to Week 12

    Change in score for items 32, 33 and 34 of Part IV of the Unified Parkinson?s Disease Rating Scale (UPDRS ) from baseline to Week 12

    other secondary objectives may be defined in the protocol
    - Cambio en la puntuación total de la escala UDysRS Parts I, II, III, y IV desde baseline a semana 12

    - Cambio en la puntuación total de la escala LFADLDS desde baseline a semana 12

    - Cambio en la puntuación total de la escala CGIC desde baseline a semana 12

    - Cambios en los peridodos ON y OFF y ON con discinesias y con discinesias discapacitantes (diario del paciente) desde baseline a semana 12

    - Cambio en la puntuación de los items 32, 33 y 34 de la Parte IV de la escala UPDRS desde baseline a semana 12.

    - otros objetios secundarios pueden definirse en el protocolo
    E.5.2.1Timepoint(s) of evaluation of this end point
    - The change in total score and sub-score of UDysRS Parts I, II, III, and IV from baseline to Week 12 (week 0; 8; 12)

    - Change in Lang-Fahn Activities of Daily Living Dyskinesia Scale (LFADLDS) total score from baseline to Week 12 (week -2; 0;6; 8; 12)

    - Change in clinician-rated global impression of change (CGIC) score from baseline to Week 12 (week 0; 6; 8; 12)

    - Change from baseline Total ON- and OFF-times and ON-time with dyskinesia and with troublesome dyskinesias (patient diary) to Week 12 (week 0; 6; 8; 12)

    - Change in score for items 32, 33 and 34 of Part IV of the Unified Parkinson's Disease Rating Scale (UPDRS ) from baseline to Week 12(week -6 to -3; -2; 0; 8; 12; 13)

    - other secondary objectives may be defined in the protocol
    - semanas 0; 8; 12

    - semanas -2; 0; 6; 8; 12

    - semanas 0; 6; 8; 12

    - semanas 0; 6; 8; 12

    - semanas -6 a -3; -2; 0; 8; 12; 13

    - otros objetios secundarios pueden definirse en el protocolo
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA31
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    France
    Germany
    Hungary
    Italy
    Slovakia
    Spain
    Switzerland
    Turkey
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LPLV
    última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 92
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 45
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state15
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 60
    F.4.2.2In the whole clinical trial 92
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    A long term open label extension study with AFQ056 will be initiated. Patients who have completed the current study and who meet the inclusion/exclusion criteria for the open label treatment study will be eligible to enter that study.
    Se iniciará una extensión abierta con AFQ056 (CAFQ056A2299). Los pacientes que completen este estudio y cumplan los criterios de inclusión/exclusión para el estudio de extensión de tratameinto abierto serán elegibles para entrar en el mismo.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-03-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-03-15
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 17:57:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA